Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seiji Ueda

Showing results (21-30 of 124) with videos related to

Pageof 13
Sort By:
Protein and Peptide Letters|March 11, 2010
Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitroTakanori Matsui, Sho-ichi Yamagishi, Seiji Ueda, et al.
Current Pharmaceutical Design|November 11, 2008
Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complicationsSho-ichi Yamagishi, Seiji Ueda, Kazuo Nakamura, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 13, 2019
Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal SyndromeKensei Taguchi, Bertha C Elias, Craig R Brooks, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 21, 2025
Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney DiseaseMaki Murakoshi, Takashi Kobayashi, Masao Kihara, et al.
Nephrology (Carlton, Vic.)|June 26, 2023
The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney diseaseMaki Murakoshi, Takashi Kobayashi, Masao Kihara, et al.
Pharmacological Research|July 29, 2009
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expressionTakanori Matsui, Sho-Ichi Yamagishi, Masayoshi Takeuchi, et al.
Expert Opinion on Investigational Drugs|June 14, 2008
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complicationsSho-Ichi Yamagishi, Kazuo Nakamura, Takanori Matsui, et al.
Biochimica Et Biophysica Acta|March 29, 2011
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetesSho-ichi Yamagishi, Sayaka Maeda, Takanori Matsui, et al.
Biochemical and Biophysical Research Communications|May 23, 2009
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activationTakanori Matsui, Sho-ichi Yamagishi, Masayoshi Takeuchi, et al.
Thrombosis Research|February 1, 2015
Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 systemYuji Ishibashi, Takanori Matsui, Kei Fukami, et al.
Pageof 13

Showing results (21-30 of 124) with videos related to

Sort By:
Pageof 13
Protein and Peptide Letters|March 11, 2010
Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitroTakanori Matsui, Sho-ichi Yamagishi, Seiji Ueda, et al.
Current Pharmaceutical Design|November 11, 2008
Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complicationsSho-ichi Yamagishi, Seiji Ueda, Kazuo Nakamura, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 13, 2019
Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal SyndromeKensei Taguchi, Bertha C Elias, Craig R Brooks, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 21, 2025
Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney DiseaseMaki Murakoshi, Takashi Kobayashi, Masao Kihara, et al.
Nephrology (Carlton, Vic.)|June 26, 2023
The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney diseaseMaki Murakoshi, Takashi Kobayashi, Masao Kihara, et al.
Pharmacological Research|July 29, 2009
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expressionTakanori Matsui, Sho-Ichi Yamagishi, Masayoshi Takeuchi, et al.
Expert Opinion on Investigational Drugs|June 14, 2008
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complicationsSho-Ichi Yamagishi, Kazuo Nakamura, Takanori Matsui, et al.
Biochimica Et Biophysica Acta|March 29, 2011
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetesSho-ichi Yamagishi, Sayaka Maeda, Takanori Matsui, et al.
Biochemical and Biophysical Research Communications|May 23, 2009
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activationTakanori Matsui, Sho-ichi Yamagishi, Masayoshi Takeuchi, et al.
Thrombosis Research|February 1, 2015
Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 systemYuji Ishibashi, Takanori Matsui, Kei Fukami, et al.
Pageof 13